JMT-106

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameJMT-106
Drug Alias NameJMT106JMT-106
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionGlypican-3 modulatorsInterferon receptors modulators
TargetsGlypican-3Interferon receptors
Therapy Area/IndicationsSolid tumoursCarcinoma, Squamous CellCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdShanghai Jmt-Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Squamous CellCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A